ArticleTherapeutic innovation & regulatory science2026
Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite widespread receptivity to risk-based quality management (RBQM) principles, adoption has been limited as drug development stakeholders have lacked quantitative evidence demonstrating return on investment (ROI).
methodsTwo assessments were conducted to estimate the ROI of RBQM. (1) Clinical trial level ROI was derived by analyzing monitoring cost efficiencies and clinical phase duration reductions under a 10% source data verification (SDV) scenario. (2) Program-level ROI was derived using an expected net present value (eNPV) modeling approach. Both analyses included data based on actual RBQM use in 18 recently completed oncology trials, as well as published and proprietary industry benchmarks.
resultsRBQM use was associated with reductions of 8-19% in clinical phase durations and monitoring cost reductions of up to 18% under a 10% SDV scenario. Total clinical trial ROIs ranged from $3.2 million (phase 1) to $18.9 million (phase 3), corresponding to ROI multiples of 6× to 23×. Program-level eNPV gains ranged from $3.8 million in phase 1 to $13.8 million in phase 3 corresponding to ROI multiples of 4× to 14×.
conclusionsThe ROI demonstrated at the individual clinical trial level and at the development program level provides a compelling business case for adopting RBQM particularly given alignment with ICH E6 R3 guidelines encouraging risk-based approaches supporting clinical trial planning and execution. Study findings indicate that RBQM-supported oversight not only improves data quality and risk detection but also represents a strategic investment that can help optimize resource allocation, increase development efficiency and speed, and enhance portfolio productivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.